Business
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"\n Revenue growth of 113% driven by strong performance in molecular profiling services\n \n \n Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year growth of 75-77%\n \n \n IRVING, Texas, Nov. 5, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended September 30, 2025.\n \n \n \n \n \n \n \n \n Third Quarter 2025 Financial Highlights\n \n \n Reported total revenue of $216.8 million, an increase of 113.4% over the corresponding prior year period.\n Completed 50,763 clinical therapy selection cases, an increase of 18.2% over the corresponding prior year period.\n Reported gross margin of 68.0%, a 2,432 bps improvement over the corresponding prior year period.\n Achieved net income of $24.3 million.\n Reported positive Adjusted EBITDA of $51.2 million.\n Reported positive net cash flow from operating activities of $62.4 million, and positive free cash flow of $55.3 million.\n Raised full-year 2025 revenue guidance to an updated range of $720 to $730 million, representing growth of 75% to 77% year-over-year.\n \n \"We delivered another record quarter for revenue and clinical volume, achieving positive net income and demonstrating the operating strength of our comprehensive, patient-first approach,\" said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences. \"These results reflect the core strength of our business and our continued progress toward delivering the next generation of personalized solutions through our exciting pipeline in MRD and early detection.\"\n \n Recent Operating Highlights\n \n \n Surpassed 959,000 total profiles and 660,000 total matched profiles through September 30, 2025.More than 577,000 Whole Exome and 628,000 Whole Transcriptome profiles through September 30, 2025.\n Published study validating optimal sequencing in informing therapy choices for breast cancer subgroups:Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis. \n Published a study validating the analytical and clinical performance of MI Cancer SeekClinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecu...